Capsule Summary Slidesets

Share

Program Content

Activities

  • Tebentafusp + Anti–PD-L1: Cutaneous Melanoma
    Tebentafusp ± Durvalumab and/or Tremelimumab in Metastatic Cutaneous Melanoma: Updated OS Analysis From IMCgp100-201 Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2022

    Expires: June 12, 2023

  • PRADO
    PRADO: Phase II Trial of Response-Directed Surgery and Adjuvant Therapy Following Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2022

    Expires: June 12, 2023

  • SWOG 1512
    SWOG 1512: Phase II Study of Neoadjuvant Pembrolizumab in Patients With Resectable Desmoplastic Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

  • NeoTrio
    NeoTrio: Neoadjuvant Pembrolizumab Alone, Combined With, or in Sequence With Dabrafenib and Trametinib in Resectable BRAFV600-Mutant Stage III Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

  • RELATIVITY-047: Subgroup Analysis
    RELATIVITY-047: OS and ORR by Key Subgroups in Patients With Advanced Melanoma Receiving First-line Relatlimab + Nivolumab vs Nivolumab Alone
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

  • CAM/APA/TMZ in Acral Melanoma
    First-line Camrelizumab, Apatinib, and Temozolomide in Advanced Acral Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2022

    Expires: June 12, 2023

  • AMBER Parts 1C and 1E
    AMBER Parts 1C and 1E: Phase I Trial of Cobolimab, an Anti–TIM-3 mAb, Plus Dostarlimab in Advanced Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 20, 2022

    Expires: June 19, 2023

  • TRICOTEL
    TRICOTEL: Phase II Study of Atezolizumab, Cobimetinib, and Vemurafenib in BRAFV600-Mutated Melanoma With CNS Metastases
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 15, 2022

    Expires: June 14, 2023

  • CheckMate 067: 7.5-Yr Update
    CheckMate 067: Long-term Survival and HRQoL With First-line Nivolumab ± Ipilimumab in Advanced Melanoma at 7.5-Yr Follow-up
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2022

    Expires: June 15, 2023

  • KEYNOTE-716 Update
    KEYNOTE-716: Update of the Phase III Trial of Adjuvant Pembrolizumab vs Placebo in Stage IIB/IIC Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab